Last reviewed: June 6, 2026 Last updated: June 6, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Because it shares pharmacological features with licensed GLP-1 receptor agonists such as semaglutide and tirzepatide, clinically relevant interactions including with antidiabetic medicines, anticoagulants, and narrow therapeutic index drugs can be anticipated
Free radical initiators as source of water- or lipid-soluble peroxyl radicals
twice-daily injections typical for injectable protocols No refrigeration needed (capsules stable at room temperature) Convenient for travel and busy schedules Dietary supplement status (no prescription required) Injectable Characteristics: Potentially higher bioavailability reaching systemic circulation (comparative human data does not exist) Established user base with extensive anecdotal reports Ability to perform local injection near injury sites Dosing protocols from practitioner guidance more available Consideration: Oral BPC-157 suits needle-averse beginners prioritizing convenience
This is a serious situation, best addressed by a doctor